疾病预防控制中心20-PBRM1选择性自降解媒介影响细胞癌的免疫治疗
Yizeng Fan1,2,3, Weichao Dan1,2,3, Taotao Que1,2,3
1Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 10, 2024
概括
用一种新型来向Polybromo 1 (PBRM1) 增强了癌中免疫疗法的疗效. 这种方法提高了野生型PBRM1患者的抗PD-1治疗有效性,提高了生存率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 在Polybromo 1 (PBRM1) 中的非活化突变与清细胞脏细胞癌 (ccRCC) 免疫检查点抑制剂的积极反应相关.
- 对于野生型PBRM1患者的免疫疗法疗效中PBRM1的作用及其蛋白质稳定性调节的作用仍未得到充分研究.
研究的目的:
- 调查向PBRM1的潜力,以提高ccRCC中免疫疗法的疗效.
- 阐明调节PBRM1蛋白稳定的上游途径.
- 为患有野生型PBRM1.1的ccRCC患者开发一种新的治疗策略.
主要方法:
- 进行了PBRM1淘汰,以评估其对巨细胞两极分化和细胞癌 (RCC) 抗PD-1免疫疗法的疗效的影响.
- 研究了CDC20在PBRM1无化和通过选择性自降解中的作用.
- 一种双循环 (PB1-p62) 旨在准PBRM1和p62,从而促进PBRM1的降解.
主要成果:
- 抑制PBRM1促进了M1巨细胞的两极分化和透,增强了抗PD-1免疫疗法的疗效.
- 鉴定出CDC20是PBRM1的K27无化催化剂,通过p62-介导的选择性自促进其降解.
- PB1-p62成功促进了PBRM1的降解,从而提高了抗PD-1免疫疗法的疗效,并改善了小鼠瘤模型的整体存活率.
结论:
- 通过PB1-p62来向PBRM1降解提供了一种新的策略,以增强与野生型PBRM1.1RCC患者的抗PD-1免疫疗法.
- 这种方法显示了临床应用的潜力,可以改善RCC的治疗结果.
- 这项研究为PBRM1调节及其在瘤免疫微环境中的作用提供了新的见解.
相关概念视频
01:27Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Autophagy
4.2K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:27Cytotoxic T Cells-mediated Immune Response
846
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
846